Shares dropped 5.2% following earnings, reflecting investor disappointment primarily driven by cautious outlook and limited new financial guidance amid ongoing clinical developments.
- Delivered multiple positive clinical data sets in RNAi and RNA editing pipelines, notably WVE-007 for obesity and WVE-006 for AATD.
- Phase IIa trial of WVE-007 underway, targeting higher-risk obesity patients with comorbidities; additional combo and maintenance trials planned.
- Received FDA acceptance for Phase IIa INLIGHT trial amendment; meeting with FDA on accelerated approval pathway for WVE-006 expected late summer.
- Advancing WVE-008 targeting PNPLA3 liver disease with planned CTA filing later this year; RNA editing approach uniquely positioned given silencing limitations.
- No new financial guidance or updates were provided, leaving questions on near-term commercial visibility and growth, which likely weighed on shares.
Community Discussion